COMP <GO>
ACHC vs LLY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Acadia Healthcare Company Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ACHC 2
— LLY 10
■ METRIC PARITY
LAST: $29.46 (-0.17%) • MKT CAP: $2.74B
options-implied-move
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
options-implied-move
6.77%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACHC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.80% | 32.36% | -57.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.04% | 2.30% | -18.34 | LLY | /fcf-yield <GO> |
| Operating Margin | -40.60% | 40.21% | -80.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | -33.30% | 31.90% | -65.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 45.51% | -40.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 9.29 | -8.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 66.6 | -19.30 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.51 | +0.56 | ACHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 26.3x | -5.25 | ACHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.74B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACHC REV | LLY REV | ACHC GROSS % | LLY GROSS % | ACHC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.31B | $65.18B | — | 83.0% | -$439.9M | $16.81B |
| FY 2024 | $3.15B | $45.04B | — | 81.3% | -$560.7M | $8.82B |
| FY 2023 | $2.93B | $34.12B | — | 79.3% | $330.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHC // BETA 1.07
LLY // BETA 0.51